Extracorporeal Membrane Oxygenation Machine Market: Global Industry Analysis and Forecast (2023-2029)

Extracorporeal Membrane Oxygenation Machine Market size was valued at USD 569.7  Mn. in 2022 and the total Extracorporeal Membrane Oxygenation Machine revenue is expected to grow by 5.5 % from 2023 to 2029, reaching nearly USD 828.7 Mn.
Extracorporeal Membrane Oxygenation Machine Market Overview:
The Extracorporeal membrane oxygenation (ECMO) is a life-sustaining technology that provides cardiac and respiratory support to individuals with severe respiratory failure. The ECMO circuit is made up of cannulas, a pump, a blender, and an oxygenator, which oxygenates the blood and removes carbon dioxide via an extracorporeal gas exchange device known as a membrane oxygenator. Severe acute respiratory distress syndrome (ARDS), acute hypercapnic respiratory failure, bridge lung transplantation, primary graft malfunction post-lung transplantation, and pulmonary hypertension with right ventricular failure are also potential indications for ECMO usage.

The growing geriatric population and increase in illness incidence, as well as favorable government laws, investments, and initiatives are the primary drivers driving the growth of this ECMO Machine Market. The benefits of ECMO devices have aided in their acceptance; their speed and precision, as well as quick processing times, allow for substantially greater patient screening numbers than previously. This has compelled businesses to concentrate on product development and innovation. However, these systems are expensive, which inhibits their widespread implementation. Other limitations such as falling reimbursements, a lack of infrastructure, particularly in emerging and poor nations, and possible dangers connected with radiation exposure are expected to hamper the market growth.
Research Methodology:
The report's goal is to give complete assessment estimates using an appropriate set of assumptions and methodology. By defining and analyzing market segments and predicting worldwide market size, the research aids in understanding the Extracorporeal Membrane Oxygenation Machine Market dynamics and structure. Additionally, the study examines the competitive landscape of key competitors in terms of product, pricing, financial situation, growth plans, and geographical presence.

The research has covered the PEST analysis by region and important economies throughout the world, which are expected to have an influence on the market during the forecasted period, to better understand market dynamics and by region. To examine their tactics, PORTER conducted market research as well as a complete SWOT analysis of important companies. The study covers all stakeholder concerns about prioritizing efforts and investments in the Extracorporeal Membrane Oxygenation Machine Market's developing segment in the forecast period.To know about the Research Methodology :- Request Free Sample Report
Extracorporeal Membrane Oxygenation Machine Market Dynamics:
Market Drivers:

Demand for disease prevention

The increased prevalence of cardiopulmonary illnesses and respiratory failures is the primary Extracorporeal Membrane Oxygenation Machine market driver. According to the Centers for Disease Control and Prevention (CDC), one person dies from cardiovascular disease every 37 seconds in the United States. Moreover, in 2019, chronic obstructive pulmonary disease (COPD) was one of the major causes of mortality in the United States. The growing use of extracorporeal membrane oxygenation (ECMO) has accelerated technical progress in these systems. The progress involves the use of hollow pumps, oxygenators, and heparin-coated cannulas in a variety of surgical applications.

The reasons driving ECMO machine market growth include an increase in the number of hospitals delivering ECMO services and an increase in the number of awareness initiatives. According to the Federal Agency for Healthcare Research and Quality, 6890 ECMO treatments were conducted in the United States in 2014. Following that, the use of extracorporeal membrane oxygenation (ECMO) equipment in hospitals has skyrocketed. According to the Extracorporeal Life Support Organization (ELSO), the number of hospitals providing ECMO treatments increased from 108 in 2008 to 280 in 2022.

ECMO machines are being utilized to treat patients with severe COVID-19. However, other applications of these devices, such as cardiac treatments, are expected to fall sharply by 2020. The growing awareness of ECMO techniques, along with technical improvement, is moving the ECMO machine market forward. Many government agencies worked to raise knowledge about ECMO procedures. Global Initiative for Chronic Obstructive Lung Disease (GOLD) initiatives aim to raise awareness of COPD and its treatment, which includes the use of ECMO devices.

Additionally, the growing use of ECMO devices is propelling technical improvement in these systems. The most recent advancements include oxygenators, hollow pumps, and heparin-coated cannulas utilized in a variety of surgical applications. Moreover, newly designed ECMO devices are lower in size, enhancing mobility and applicability. Portable adaptors and tiny ECMO machine circuits, which aid in the evacuation of critically ill patients, have also been created. The growing elderly population, along with the rising incidence of coronary heart disease, is driving up the use of ECMO machines. Coronary heart disease is a primary cause of mortality worldwide and is closely linked to age. According to the United Nations, the number of individuals aged 80 and more is expected to increase from 143 million in 2019 to 426 million by 2050.

Growing use of ECMO during lung transplant procedures

Lung transplantation has become more common in recent decades, particularly for the treatment of end-stage lung disorders such as Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease, and Cystic Fibrosis. The use of an ECMO machine in lung transplantation procedures has grown dramatically over the years in the treatment of patients with serious lung disease. The most prevalent reason for using ECMO after lung transplantation is Primary Graft Dysfunction (PGD). PGD is a condition characterized by lung injury within the first 72 hours after a lung transplant. Several studies have demonstrated favorable outcomes associated with the use of ECMO as a bridging approach as well as treatment for individuals suffering from PGD following transplant, thanks to substantial advancements in technology.

With the growing frequency of lung disorders throughout the world, the usage of ECMO machines market is expected to increase even more in the forecast years. With the growing frequency of lung disorders throughout the world, the usage of ECMO machines is expected to increase even more in the forecast years.

Market Restraints:

Expensive ECMO products

ECMO is a costly treatment. Aside from the costs of the systems, other charges include the cost of hospitalization and the cost of extra disposable accessories. Additionally, a complete team of medical specialists is necessary to care for the patient having an ECMO operation, which increases the expense of the therapy, although the cost varies depending on the duration of its usage. The normal hospital stay for a patient receiving ECMO assistance is typically 1-2 weeks; however, this time period might be extended depending on the severity of the sickness. This raises the total cost of the treatment, which most patients cannot afford.

ECMO Machine Market Opportunities:

The ECMO Machines improve survival chances

ECMO patient survival rates vary based on the underlying disease and the patient's age. VV-ECMO is intended for patients with possibly reversible respiratory failure, such as severe acute respiratory distress syndrome (ADRS), primary graft malfunction after a lung transplant, and pulmonary trauma. Patients with respiratory failure who get VV-ECMO have a higher chance of survival. Because of its potential to support failing circulatory systems with oxygenation functions, ECMO devices are also employed in cardiac applications. The use of these technologies for heart failure improves cardiac patient survival rates. Improving survival rates with ECMO is expected to offer the ECMO machine market attractive growth potential.
Extracorporeal Membrane Oxygenation Machine Market Segment Analysis:
Based on Components, The oxygenators segment accounted for 40.2% of Extracorporeal Membrane Oxygenation Machine market revenue in 2022 and is expected to increase at a profitable pace during the forecast period. The high cost and rapid exchange rate for a different system account for oxygenators' significant market size. Mechanical failure, pump head thrombosis, and acute oxygenator thrombosis are the primary causes of the oxygenator exchange rate.

Pumps have a significant market share owing to their high cost and consumption. The pumps of ECMO devices assist in pumping blood from a patient to artificial lungs, which then return the blood to the patient after oxygenation. The segment's rise owing largely to the increased use of pumps in ECMO procedures and the availability of numerous types of pumps such as roller, impeller, and centrifugal. These pumps are utilized in a variety of ECMO techniques depending on their requirements.

Based on the Modality, The veno-arterial category is expected to grow at a strong CAGR during the forecast period, accounting for 35.8% of market revenue in 2022. The segment's biggest size is partly because of its widespread use in treating cardiac arrest patients, aiding with algorithm life support measures to restore blood circulation.

The veno-venous category accounted for a considerable proportion in 2022 and is expected to increase at a profitable pace over the forecast period. The venovenous ECMO (VV ECMO) circuit's principal role is to facilitate the exchange of oxygen and carbon dioxide. As a result, it has a wide range of applications in circumstances when lung support is required. The growing prevalence of the chronic obstructive pulmonary disease is one of the primary drivers of the ECMO machine market. According to the WHO, there were 255 million cases of COPD worldwide in 2020, with this figure expected to rise further throughout the forecast period.

Based on the Patient, Adult patients accounted for 62.0% of Extracorporeal Membrane Oxygenation Machine market revenue in 2022 and are expected to expand at the quickest rate throughout the forecast period. Alcohol, tobacco, and smoking use, combined with a sedentary lifestyle, are contributing to an increase in the global burden of heart and respiratory disorders in adults. According to data provided by the Extracorporeal Life Support Organization, there were around 7,950 persons suffering from cardiac diseases that required ECMO in January 2020.

The pediatric category also had a sizable market share and is predicted to grow at a rapid rate during the forecast period. The growing number of youngsters suffering from various pulmonary cardiac ailments is one of the segment's primary drivers. According to the Extracorporeal Life Support Organization, about 8,102 youngsters suffered from cardiac disease and required ECMO therapy in January 2019.

Based on the Application, In 2022, the respiratory category held the biggest market share of 49.0% in total Extracorporeal Membrane Oxygenation Machine Market. The ECMO device is used to treat a variety of problems in babies, including meconium aspiration syndrome, pneumonia, congenital diaphragmatic hernia (CDH), and respiratory distress syndrome. Based on the patient demographic, the extracorporeal membrane oxygenation market is segmented into three segments: infant, pediatric, and adult. The risk of respiratory failure among people with various respiratory disorders is a crucial component in the segment's growth.

Additionally, increasing tobacco use and smoking harm lung health and can lead to respiratory failure or chronic disorders. Asthma and chronic obstructive pulmonary disease (COPD) are important public health costs, according to statistics published in June 2020 by the Office of Disease Prevention and Health Promotion. Specific detection, intervention, and treatment strategies may help to alleviate the load and boost health. Asthma affects more than 27 million individuals in the United States, according to data provided by the Office of Disease Prevention and Health Promotion in June 2020. COPD has been diagnosed in around 14.9 million individuals, with an additional 12.5 million persons undiagnosed. Furthermore, the aging population is likely to increase respiratory problems. The growing demand for respiratory therapy is expected to be driven by an aging population that is more sensitive to respiratory illnesses. Growing illness burdens thus boost product adoption rates in the forecast years.

The survival rates of ECMO patients vary depending on the underlying condition and the patient's age. Veno-Venous (VV) ECMO is being considered for patients with possibly reversible respiratory failure, such as severe acute respiratory distress syndrome (ADRs), primary graft malfunction following a lung transplant, and pulmonary trauma. Patients who get VV-ECMO for respiratory failure have a better probability of survival.

The growing incidence of target illnesses increased need for early detection and diagnostic imaging, and technical advancements in the ECMO machine market all contribute to market growth. ECMO is commonly utilized in babies with respiratory distress because of various advantages, including the fact that it is strongly related to low survival rates. Recent technological advancements in ECMO circuits, on the other hand, have reduced the frequency of technical defects and problems. Extracorporeal membrane oxygenation (ECMO) is growing increasingly popular, which is hastening technical advancement in these devices. Hollow pumps, oxygenators, and heparin-coated cannulas were all created and are currently used in a variety of surgical operations. All of these factors contribute to the market's segmented growth.
Regional Insights:
North America led the worldwide market and accounted for the biggest revenue share of 45%, owing to the rising incidence of cardiovascular and respiratory disorders, technical developments in ECMO technology, and increased use of ECMO systems. According to the Centers for Disease Control and Prevention (CDC), in February 2022, 659,000 individuals in the United States would die from heart disease, accounting for one out of every four fatalities. In addition, about 805,000 people in the United States experience heart attacks. The region's requirement for Extracorporeal Membrane Oxygenation (ECMO) is also growing owing to the increased adoption of new technological goods and changes in lifestyle choices that result in chronic diseases such as cardiac and respiratory ailments.

An increase in the number of improvements and sophisticated technology in this Extracorporeal Membrane Oxygenation (ECMO) devices, as well as an increase in public awareness of their many applications, has resulted in a significant quantity of output for hospitals. Additionally, in the United States, high blood pressure, obesity, type 2 diabetes, and poor eating habits have all increased the number of instances of cardiovascular disease. ECMO (extracorporeal membrane oxygenation) has the potential to reduce the number of in-hospital mortality.

Moreover, statistics published in March 2022 by the American Thoracic Society (ATS) suggest that the United States spends around USD 80.5 billion on asthma-related expenses each year. Given the high mortality rates from cardiovascular illnesses and the growing spending on asthma treatment, the business under examination has plenty of space for growth. Furthermore, the market for Extracorporeal Membrane Oxygenation (ECMO) is growing as a result of rising government healthcare spending to improve healthcare services. Furthermore. Medicare and Medicaid reimbursement regulations, which cover patients receiving Extracorporeal Membrane Oxygenation (ECMO), are expected to propel the Extracorporeal Membrane Oxygenation Machine Market. All of these variables are expected to have an influence on regional market growth.
Extracorporeal Membrane Oxygenation Machine Market Scope: Inquire before buying



Extracorporeal Membrane Oxygenation Machine Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
US $ 569.7 Mn.


Forecast Period 2023 to 2029 CAGR:
5.5%
Market Size in 2029:
US $ 828.73 Mn.


 Segments Covered:
by Component
Pumps
Oxygenator
Controllers
Cannula
Accessories


by Modality
Veno-Arterial
Veno-Venous
Arterio-Venous


by Patient
Neonates
Pediatric
Adult


by Application
Respiratory
Cardiac
ECPR



Extracorporeal Membrane Oxygenation Machine Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Players:
1. Getinge
2. Medtronic plc
3. Livanova PLC
4. Abbott
5. Abiomed
6. Cytosorbents Corporation
7. Agilent Technologies
8. Siemens AG
9. Terumo Corporation
10.Fresenius Medical Care AG & Co. KGaA
11.Microport Scientific Corporation
12.Nipro Corporation
13.ALung Technologies Inc.
14.MAQUET Holding B.V. & Co. KG
15.Medos Medizintechnik AG
16.Terumo Cardiovascular Systems Corp
17.XENIOS AG
18.OriGen Biomedical, Inc.
19.EUROSETS S.r.l.

Frequently Asked Questions:

1] Which company makes ECMO machines?
Ans. Fresenius Medical care AG & Co. KGAA (Germany), Getinge Group (Sweden), Medtronic plc (US), and Microport lead the ECMO machine market (China). Fresenius Medical Care AG & Co. KgaA is a major supplier of ECMO goods and services to patients.

2] How much does an ECMO oxygenator cost?
Ans. The mean projected cost of the ECMO procedure was 73,122 USD (SD 34,786), with a median of 62,545 USD (range: 34,121-154,817). The average projected total hospital expenses, including pre-and post-ECMO operations, were 213,246 USD (standard deviation 12,265), with a median of 191,436 USD (range: 59,871-405,497)

3] How much does it cost to be on ECMO per day?
Ans. According to various accounts, they range between USD 20,000 and 40,000 every day. 5,6 Hospitalizations for PCS-ECMO are projected to cost between USD 200,000 and 500,000, and when used as a bridge to LT, median hospital expenditures are raised by up to 50%.

4] Is ECMO profitable?
Ans. If properly put up, ECMO applications may be quite profitable. And the key point to grasp is that perfusionists increase the quality of treatment provided to patients, which leads to better outcomes, which may mean greater money for hospitals."

5] Is ECMO cost-effective?
Ans. The incremental cost-effectiveness ratio (ICER) of 2-3 weeks of ECMO over 2 weeks of ECMO is $102,585 per QALY, indicating that 2-3 weeks of ECMO is extremely cost-effective at a WTP of $200,000 per QALY.